Federal health regulators in the United States said that kid-size doses of Pfizer’s Covid-19 vaccine appear highly effective at preventing symptomatic infections in elementary school children and caused no unexpected safety issues, as the US weighs beginning vaccinations in youngsters.

The Food and Drug Administration posted its analysis of Pfizer’s data ahead of a public meeting next week to debate whether the shots are ready for the nation’s roughly 28 million children ages 5 to 11. The agency will ask a panel of outside vaccine experts to vote on that question, according to AP.

In their analysis, FDA scientists concluded that in almost every scenario the vaccine’s benefit for preventing hospitalisations and death from Covid-19 would outweigh any serious potential side effects in children. But agency reviewers stopped short of calling for Pfizer’s shot to be authorised.